
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc. has demonstrated a positive financial trajectory, highlighted by a 28% increase in share value following the announcement of Medicare coverage for its NeXT Personal MRD test, showcasing strong initial market acceptance in breast cancer. The company’s strategic decision to temper volume growth in Q3 was aimed at safeguarding margins while awaiting reimbursement, indicating prudent financial management in anticipation of increased demand. Furthermore, with a large commercial partner like Tempus expected to enhance marketing efforts and positive reimbursement decisions anticipated for additional indications, Personalis’s revenue outlook for 2026 and beyond appears promising, reflecting its potential growth opportunities in the personalized cancer treatment sector.
Bears say
Personalis Inc. faces a negative outlook primarily due to a downward revision of its revenue guidance for 2025, decreasing from a range of $70-$80 million to $68-$73 million, reflecting a year-over-year decline of 12% to 5%. The company has encountered challenges in its biopharma revenue, notably a slowdown attributed to logical issues with sample flow for minimal residual disease (MRD) testing and reimbursement delays for clinical sample testing. Additionally, significant ongoing losses, coupled with debt on the balance sheet, present concerns about the company’s ability to achieve and sustain profitability in the future.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares